Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 500946108 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Lynx1 Capital Management LP
13G/A
|
10.7% |
4/2/2026
Event 3/31/2026
|
||
| Lynx1 Capital Management LP | 10.7% | |||
| Weston Nichols | 10.7% | |||
|
Venrock Healthcare Capital Partners III, L.P.
13G
|
9.9% |
3/17/2026
Event 3/10/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | |||
| VHCP Co-Investment Holdings III, LLC | 9.9% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | |||
| VHCP Management III, LLC | 9.9% | |||
| VHCP Management EG, LLC | 9.9% | |||
| Nimish Shah | 9.9% | |||
| Bong Y. Koh | 9.9% | |||
|
New Enterprise Associates 17, L.P.
13D/A
|
9.9% |
3/12/2026
Event 3/10/2026
|
||
| New Enterprise Associates 17, L.P. | 9.9% | |||
| NEA Partners 17, L.P. | 9.9% | |||
| Nea 17 GP, LLC | 9.9% | |||
| Forest Baskett | 9.9% | |||
| Ali Behbahani | 9.9% | |||
| Carmen Chang | 9.9% | |||
| Anthony A. Florence, Jr. | 9.9% | |||
| Mohamad H. Makhzoumi | 9.9% | |||
| Edward T. Mathers | 9.9% | |||
| Scott D. Sandell | 9.9% | |||
| Paul Walker | 9.9% | |||
| Rick Yang | 9.9% | |||
|
Balyasny Asset Management L.P.
13G/A
|
6.6% |
8/14/2026
Event 6/30/2026
|
||
| Balyasny Asset Management L.P. | 6.6% | |||
| Bam GP LLC | 6.6% | |||
| Balyasny Asset Management Holdings LP | 6.6% | |||
| Dames GP LLC | 6.6% | |||
| Dmitry Balyasny | 6.6% | |||
|
Nantahala Capital Management, LLC
13G
|
6.4% |
2/13/2026
Event 12/31/2025
|
||
| Nantahala Capital Management, LLC | 6.4% | |||
| Wilmot B. Harkey | 6.4% | |||
| Daniel Mack | 6.4% | |||
| BlackRock, Inc. 13G | 5.2% |
7/29/2026
Event 6/30/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (8) | ||||
|
Atlas Venture Fund XI, L.P.
13D/A
|
4.9% |
8/4/2026
Event 6/24/2026
|
||
| Atlas Venture Fund XI, L.P. | 4.9% | |||
| Atlas Venture Associates XI, L.P. | 4.9% | |||
| Atlas Venture Associates XI, LLC | 4.9% | |||
| Atlas Venture Opportunity Fund II, L.P. | 1.0% | |||
| Atlas Venture Associates Opportunity II, L.P. | 1.0% | |||
| Atlas Venture Associates Opportunity II, LLC | 1.0% | |||
|
Citadel Advisors LLC
13G/A
|
3.9% |
2/14/2025
Event 12/31/2024
|
||
| Citadel Advisors LLC | 3.9% | |||
| Citadel Advisors Holdings LP | 3.9% | |||
| Citadel GP LLC | 3.9% | |||
| Citadel Securities LLC | 0% | |||
| Citadel Securities Group LP | 0% | |||
| Citadel Securities GP LLC | 0% | |||
| Kenneth Griffin | 3.9% | |||
|
Deep Track Capital, LP
13G/A
|
3.0% |
8/14/2025
Event 6/30/2025
|
||
| Deep Track Capital, LP | 3.0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 3.0% | |||
| David Kroin | 3.0% | |||
|
Point72 Asset Management, L.P.
13G/A
|
1.9% |
5/15/2026
Event 3/31/2026
|
||
| Point72 Asset Management, L.P. | 0% | |||
| Point72 Capital Advisors, Inc. | 0% | |||
| Point72 Biotech Private Investments, LLC | 1.9% | |||
| Differentiated Ventures Investments, LLC | 1.9% | |||
| 72 Investment Holdings, LLC | 1.9% | |||
| Steven A. Cohen | 1.9% | |||
|
FMR LLC
13G/A
|
0.4% |
2/5/2026
Event 12/31/2025
|
||
| FMR LLC | 0.4% | |||
| Abigail P. Johnson | 0.4% | |||
| AllianceBernstein L.P. 13G/A | 0.1% |
8/13/2025
Event 6/30/2025
|
||
| Driehaus Capital Management LLC 13G/A | 0% |
2/17/2026
Event 12/31/2025
|
||
| Vanguard Group Inc 13G/A | 0% |
3/27/2026
Event 3/13/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 1.84 k | $18.2 k |
| 2026 Q2 | 113 | 15.1 M | $199 M |
| 2026 Q1 | 105 | 12.8 M | $145 M |
| 2025 Q4 | 88 | 7.56 M | $60.6 M |
| 2025 Q3 | 94 | 9.96 M | $475 M |
| 2025 Q2 | 73 | 9.08 M | $115 M |
| 2025 Q1 | 76 | 9.70 M | $169 M |
| 2024 Q4 | 85 | 9.45 M | $360 M |
| 2024 Q3 | 73 | 8.55 M | $286 M |
| 2024 Q2 | 67 | 8.45 M | $286 M |
| 2024 Q1 | 53 | 6.94 M | $621 M |
| 2023 Q4 | 44 | 6.57 M | $302 M |